The expression of the miRNA-200 family in endometrial endometrioid carcinoma

Jeong Won Lee, Young Ae Park, Jung Joo Choi, Yoo Young Lee, Chul Jung Kim, Chelhun Choi, Tae Joong Kim, Nak Woo Lee, Byoung Gie Kim, Duk Soo Bae

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Objective.: Recent reports suggest that targeting the unique miRNAs highly expressed in several cancers may be a promising approach in the development of new cancer therapeutic tools. The purpose of this study was to evaluate the roles of miRNAs as therapeutic targets in human endometrial endometrioid carcinomas (EECs). Methods.: We evaluated the differential expressions of miRNAs in EECs and normal endometrial tissues using microarrays and cluster analysis. After validation of differentially expressed miRNAs in another set of EECs and normal endometrial tissues, we performed the in vitro experiment using endometrial cancer cells with anti-miRNA (anti-miR) to evaluate the roles of miRNAs that are highly expressed in EECs for cell proliferation and chemosensitivity. Results.: A miRNA microarray showed that the miR-200 family, including hsa-miR-141, hsa-miR-200a, hsa-miR-200b, hsa-miR-200c, and hsa-miR-429, was up-regulated in EECs as compared with that in normal endometrial tissues. When we treated endometrial cancer cells with specific anti-miRs, including anti-miR-141, -200a, -200b, -200c, or -429, we found that anti-miR-200a, -200b, -200c, and -429 significantly inhibited the growth of HEC-1A cells and anti-miR-141, -200c, and -429 significantly inhibited the growth of Ishikawa cells. Moreover, transfection with anti-miR-429 enhanced the cytotoxic effect of cisplatin in HEC-1A cells. Conclusions.: These results indicate that the miR-200 family is highly expressed in EECs compared with that of normal endometrial tissues and could play an important role in cancer growth. Specifically, anti-miR-429 could enhance the cytotoxic activity with cisplatin in EECs. Therefore, the miR-200 family may offer new candidate targets to be exploited in therapeutic strategies for patients with these carcinomas.

Original languageEnglish
Pages (from-to)56-62
Number of pages7
JournalGynecologic Oncology
Volume120
Issue number1
DOIs
Publication statusPublished - 2011 Jan 1

Fingerprint

Endometrioid Carcinoma
Endometrial Neoplasms
MicroRNAs
Cisplatin
Growth
Tissue Array Analysis
Neoplasms
Transfection
Cluster Analysis
Therapeutics
Cell Proliferation
Carcinoma

Keywords

  • Chemotherapy
  • Endometrioid carcinoma
  • MicroRNA
  • MiR-200 family
  • Uterine carcinoma

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Lee, J. W., Park, Y. A., Choi, J. J., Lee, Y. Y., Kim, C. J., Choi, C., ... Bae, D. S. (2011). The expression of the miRNA-200 family in endometrial endometrioid carcinoma. Gynecologic Oncology, 120(1), 56-62. https://doi.org/10.1016/j.ygyno.2010.09.022

The expression of the miRNA-200 family in endometrial endometrioid carcinoma. / Lee, Jeong Won; Park, Young Ae; Choi, Jung Joo; Lee, Yoo Young; Kim, Chul Jung; Choi, Chelhun; Kim, Tae Joong; Lee, Nak Woo; Kim, Byoung Gie; Bae, Duk Soo.

In: Gynecologic Oncology, Vol. 120, No. 1, 01.01.2011, p. 56-62.

Research output: Contribution to journalArticle

Lee, JW, Park, YA, Choi, JJ, Lee, YY, Kim, CJ, Choi, C, Kim, TJ, Lee, NW, Kim, BG & Bae, DS 2011, 'The expression of the miRNA-200 family in endometrial endometrioid carcinoma', Gynecologic Oncology, vol. 120, no. 1, pp. 56-62. https://doi.org/10.1016/j.ygyno.2010.09.022
Lee, Jeong Won ; Park, Young Ae ; Choi, Jung Joo ; Lee, Yoo Young ; Kim, Chul Jung ; Choi, Chelhun ; Kim, Tae Joong ; Lee, Nak Woo ; Kim, Byoung Gie ; Bae, Duk Soo. / The expression of the miRNA-200 family in endometrial endometrioid carcinoma. In: Gynecologic Oncology. 2011 ; Vol. 120, No. 1. pp. 56-62.
@article{8bdbe3b41518455f92f3d9cf3136cc59,
title = "The expression of the miRNA-200 family in endometrial endometrioid carcinoma",
abstract = "Objective.: Recent reports suggest that targeting the unique miRNAs highly expressed in several cancers may be a promising approach in the development of new cancer therapeutic tools. The purpose of this study was to evaluate the roles of miRNAs as therapeutic targets in human endometrial endometrioid carcinomas (EECs). Methods.: We evaluated the differential expressions of miRNAs in EECs and normal endometrial tissues using microarrays and cluster analysis. After validation of differentially expressed miRNAs in another set of EECs and normal endometrial tissues, we performed the in vitro experiment using endometrial cancer cells with anti-miRNA (anti-miR) to evaluate the roles of miRNAs that are highly expressed in EECs for cell proliferation and chemosensitivity. Results.: A miRNA microarray showed that the miR-200 family, including hsa-miR-141, hsa-miR-200a, hsa-miR-200b, hsa-miR-200c, and hsa-miR-429, was up-regulated in EECs as compared with that in normal endometrial tissues. When we treated endometrial cancer cells with specific anti-miRs, including anti-miR-141, -200a, -200b, -200c, or -429, we found that anti-miR-200a, -200b, -200c, and -429 significantly inhibited the growth of HEC-1A cells and anti-miR-141, -200c, and -429 significantly inhibited the growth of Ishikawa cells. Moreover, transfection with anti-miR-429 enhanced the cytotoxic effect of cisplatin in HEC-1A cells. Conclusions.: These results indicate that the miR-200 family is highly expressed in EECs compared with that of normal endometrial tissues and could play an important role in cancer growth. Specifically, anti-miR-429 could enhance the cytotoxic activity with cisplatin in EECs. Therefore, the miR-200 family may offer new candidate targets to be exploited in therapeutic strategies for patients with these carcinomas.",
keywords = "Chemotherapy, Endometrioid carcinoma, MicroRNA, MiR-200 family, Uterine carcinoma",
author = "Lee, {Jeong Won} and Park, {Young Ae} and Choi, {Jung Joo} and Lee, {Yoo Young} and Kim, {Chul Jung} and Chelhun Choi and Kim, {Tae Joong} and Lee, {Nak Woo} and Kim, {Byoung Gie} and Bae, {Duk Soo}",
year = "2011",
month = "1",
day = "1",
doi = "10.1016/j.ygyno.2010.09.022",
language = "English",
volume = "120",
pages = "56--62",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - The expression of the miRNA-200 family in endometrial endometrioid carcinoma

AU - Lee, Jeong Won

AU - Park, Young Ae

AU - Choi, Jung Joo

AU - Lee, Yoo Young

AU - Kim, Chul Jung

AU - Choi, Chelhun

AU - Kim, Tae Joong

AU - Lee, Nak Woo

AU - Kim, Byoung Gie

AU - Bae, Duk Soo

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Objective.: Recent reports suggest that targeting the unique miRNAs highly expressed in several cancers may be a promising approach in the development of new cancer therapeutic tools. The purpose of this study was to evaluate the roles of miRNAs as therapeutic targets in human endometrial endometrioid carcinomas (EECs). Methods.: We evaluated the differential expressions of miRNAs in EECs and normal endometrial tissues using microarrays and cluster analysis. After validation of differentially expressed miRNAs in another set of EECs and normal endometrial tissues, we performed the in vitro experiment using endometrial cancer cells with anti-miRNA (anti-miR) to evaluate the roles of miRNAs that are highly expressed in EECs for cell proliferation and chemosensitivity. Results.: A miRNA microarray showed that the miR-200 family, including hsa-miR-141, hsa-miR-200a, hsa-miR-200b, hsa-miR-200c, and hsa-miR-429, was up-regulated in EECs as compared with that in normal endometrial tissues. When we treated endometrial cancer cells with specific anti-miRs, including anti-miR-141, -200a, -200b, -200c, or -429, we found that anti-miR-200a, -200b, -200c, and -429 significantly inhibited the growth of HEC-1A cells and anti-miR-141, -200c, and -429 significantly inhibited the growth of Ishikawa cells. Moreover, transfection with anti-miR-429 enhanced the cytotoxic effect of cisplatin in HEC-1A cells. Conclusions.: These results indicate that the miR-200 family is highly expressed in EECs compared with that of normal endometrial tissues and could play an important role in cancer growth. Specifically, anti-miR-429 could enhance the cytotoxic activity with cisplatin in EECs. Therefore, the miR-200 family may offer new candidate targets to be exploited in therapeutic strategies for patients with these carcinomas.

AB - Objective.: Recent reports suggest that targeting the unique miRNAs highly expressed in several cancers may be a promising approach in the development of new cancer therapeutic tools. The purpose of this study was to evaluate the roles of miRNAs as therapeutic targets in human endometrial endometrioid carcinomas (EECs). Methods.: We evaluated the differential expressions of miRNAs in EECs and normal endometrial tissues using microarrays and cluster analysis. After validation of differentially expressed miRNAs in another set of EECs and normal endometrial tissues, we performed the in vitro experiment using endometrial cancer cells with anti-miRNA (anti-miR) to evaluate the roles of miRNAs that are highly expressed in EECs for cell proliferation and chemosensitivity. Results.: A miRNA microarray showed that the miR-200 family, including hsa-miR-141, hsa-miR-200a, hsa-miR-200b, hsa-miR-200c, and hsa-miR-429, was up-regulated in EECs as compared with that in normal endometrial tissues. When we treated endometrial cancer cells with specific anti-miRs, including anti-miR-141, -200a, -200b, -200c, or -429, we found that anti-miR-200a, -200b, -200c, and -429 significantly inhibited the growth of HEC-1A cells and anti-miR-141, -200c, and -429 significantly inhibited the growth of Ishikawa cells. Moreover, transfection with anti-miR-429 enhanced the cytotoxic effect of cisplatin in HEC-1A cells. Conclusions.: These results indicate that the miR-200 family is highly expressed in EECs compared with that of normal endometrial tissues and could play an important role in cancer growth. Specifically, anti-miR-429 could enhance the cytotoxic activity with cisplatin in EECs. Therefore, the miR-200 family may offer new candidate targets to be exploited in therapeutic strategies for patients with these carcinomas.

KW - Chemotherapy

KW - Endometrioid carcinoma

KW - MicroRNA

KW - MiR-200 family

KW - Uterine carcinoma

UR - http://www.scopus.com/inward/record.url?scp=78649906875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649906875&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2010.09.022

DO - 10.1016/j.ygyno.2010.09.022

M3 - Article

C2 - 21035172

AN - SCOPUS:78649906875

VL - 120

SP - 56

EP - 62

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -